Showing results (981-990 of 1,000) with videos related to

Sort By:
Pageof 100
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L Telli, Kirsten M Timms, Julia Reid, et al.
Circulation|November 14, 2023
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial FunctionWeiyi Xu, Cyrielle Billon, Hui Li, et al.
Blood Advances|January 6, 2023
A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemiaKatherine E Masih, Rebecca A Gardner, Hsien-Chao Chou, et al.
Neuro-Oncology|March 12, 2025
Locoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical TrialJuliane Gust, Bonnie L Cole, Rebecca Ronsley, et al.
Journal for Immunotherapy of Cancer|October 29, 2020
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responsesKatherine J Brempelis, Courtney M Cowan, Shannon A Kreuser, et al.
Neoplasia (New York, N.Y.)|January 4, 2023
Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safetyNicholas A Vitanza, Rebecca Ronsley, Michelle Choe, et al.
The Journal of Pathology|November 19, 2016
The molecular basis of breast cancer pathological phenotypesYujing J Heng, Susan C Lester, Gary Mk Tse, et al.
Biorxiv : the Preprint Server for Biology|September 18, 2025
The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heartKelsey H Fisher-Wellman, Richard D Lutze, Logan G Kirkland, et al.
The Journal of Clinical Investigation|March 19, 2024
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosingJacob Appelbaum, April E Price, Kaori Oda, et al.
Science Advances|July 10, 2026
The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heartKelsey H Fisher-Wellman, Richard D Lutze, Logan G Kirkland, et al.
Pageof 100